Logo image of APRE

APREA THERAPEUTICS INC (APRE) Stock Fundamental Analysis

NASDAQ:APRE - Nasdaq - US03836J2015 - Common Stock - Currency: USD

1.81  -0.13 (-6.7%)

Fundamental Rating

3

Taking everything into account, APRE scores 3 out of 10 in our fundamental rating. APRE was compared to 558 industry peers in the Biotechnology industry. While APRE seems to be doing ok healthwise, there are quite some concerns on its profitability. APRE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APRE had negative earnings in the past year.
In the past year APRE has reported a negative cash flow from operations.
In the past 5 years APRE always reported negative net income.
In the past 5 years APRE always reported negative operating cash flow.
APRE Yearly Net Income VS EBIT VS OCF VS FCFAPRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -69.63%, APRE is not doing good in the industry: 63.98% of the companies in the same industry are doing better.
APRE has a Return On Equity (-83.51%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -69.63%
ROE -83.51%
ROIC N/A
ROA(3y)-163.39%
ROA(5y)-122.63%
ROE(3y)-186.11%
ROE(5y)-140.49%
ROIC(3y)N/A
ROIC(5y)N/A
APRE Yearly ROA, ROE, ROICAPRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

APRE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APRE Yearly Profit, Operating, Gross MarginsAPRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K -2.5K

More info and screens

6

2. Health

2.1 Basic Checks

APRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
APRE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, APRE has more shares outstanding
There is no outstanding debt for APRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APRE Yearly Shares OutstandingAPRE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
APRE Yearly Total Debt VS Total AssetsAPRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

APRE has an Altman-Z score of -22.77. This is a bad value and indicates that APRE is not financially healthy and even has some risk of bankruptcy.
APRE has a Altman-Z score of -22.77. This is amonst the worse of the industry: APRE underperforms 86.38% of its industry peers.
APRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.77
ROIC/WACCN/A
WACC9.01%
APRE Yearly LT Debt VS Equity VS FCFAPRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 5.90 indicates that APRE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.90, APRE is in the better half of the industry, outperforming 60.57% of the companies in the same industry.
A Quick Ratio of 5.90 indicates that APRE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.90, APRE is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.9
Quick Ratio 5.9
APRE Yearly Current Assets VS Current LiabilitesAPRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

APRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.35%, which is quite impressive.
The Revenue has grown by 33.15% in the past year. This is a very strong growth!
EPS 1Y (TTM)40.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.97%
Revenue 1Y (TTM)33.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-57.35%

3.2 Future

The Earnings Per Share is expected to grow by 24.42% on average over the next years. This is a very strong growth
Based on estimates for the next years, APRE will show a very strong growth in Revenue. The Revenue will grow by 144.87% on average per year.
EPS Next Y34.86%
EPS Next 2Y13.14%
EPS Next 3Y15.3%
EPS Next 5Y24.42%
Revenue Next Year-32.8%
Revenue Next 2Y-18.02%
Revenue Next 3Y147.63%
Revenue Next 5Y144.87%

3.3 Evolution

APRE Yearly Revenue VS EstimatesAPRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
APRE Yearly EPS VS EstimatesAPRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APRE. In the last year negative earnings were reported.
Also next year APRE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APRE Price Earnings VS Forward Price EarningsAPRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APRE Per share dataAPRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

APRE's earnings are expected to grow with 15.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.14%
EPS Next 3Y15.3%

More info and screens

0

5. Dividend

5.1 Amount

APRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APREA THERAPEUTICS INC

NASDAQ:APRE (6/5/2025, 8:27:51 PM)

1.81

-0.13 (-6.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners35%
Inst Owner Change-6.11%
Ins Owners11.85%
Ins Owner Change0.39%
Market Cap10.01M
Analysts84.44
Price Target10.71 (491.71%)
Short Float %1.31%
Short Ratio1.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-32.98%
EPS NQ rev (1m)-93.22%
EPS NQ rev (3m)-93.22%
EPS NY rev (1m)-2.08%
EPS NY rev (3m)-2.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.79
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)-1.71
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS0.23
BVpS3.05
TBVpS3.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.63%
ROE -83.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-163.39%
ROA(5y)-122.63%
ROE(3y)-186.11%
ROE(5y)-140.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.9
Quick Ratio 5.9
Altman-Z -22.77
F-Score4
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.97%
EPS Next Y34.86%
EPS Next 2Y13.14%
EPS Next 3Y15.3%
EPS Next 5Y24.42%
Revenue 1Y (TTM)33.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-57.35%
Revenue Next Year-32.8%
Revenue Next 2Y-18.02%
Revenue Next 3Y147.63%
Revenue Next 5Y144.87%
EBIT growth 1Y-9.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.83%
EBIT Next 3Y-13.73%
EBIT Next 5Y-10.25%
FCF growth 1Y41.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.08%
OCF growth 3YN/A
OCF growth 5YN/A